MBX Biosciences (MBX) Assets Average (2024 - 2026)

MBX Biosciences (MBX) has 3 years of Assets Average data on file, last reported at $418.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 62.86% year-over-year to $418.9 million; the trailing twelve-month figure through Mar 2026 stood at $418.9 million (up 62.86% YoY), and the FY2025 full-year result was $326.8 million, up 85.33% from the prior year.
• Assets Average advanced to $418.9 million in Q1 2026, from $392.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $418.9 million in Q1 2026 to a low of $238.7 million in Q2 2025.
• A 3-year average of $316.5 million and a median of $295.6 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 42.52% in 2025 and surged 62.86% in 2026, its largest moves.
• Tracing MBX's Assets Average over 3 years: stood at $275.5 million in 2024, then soared by 42.52% to $392.6 million in 2025, then rose by 6.7% to $418.9 million in 2026.
• Business Quant data shows MBX's Assets Average at $418.9 million in Q1 2026, $392.6 million in Q4 2025, and $315.8 million in Q3 2025.